Statin Alternatives: Ezetimibe, PCSK9, Bempedoic Acid, and What to Ask Your Doctor

October 29, 2026 Modified date: October 29, 2026

Compare ezetimibe, PCSK9 therapies, and bempedoic acid for lowering LDL, including benefits, side effects, typical LDL reductions, and questions to ask your doctor.

Statins remain the first-choice cholesterol medicine for many people because they lower LDL cholesterol and have extensive evidence for preventing heart attacks and strokes. But a statin is not the only way to lower LDL. Some people develop side effects, cannot tolerate an effective dose, have LDL that stays above goal despite treatment, or have a condition that requires a larger reduction than a statin alone can provide. In those situations, ezetimibe, PCSK9-targeting medicines, and bempedoic acid are among the most useful alternatives or add-on treatments.

The best choice depends on how far your LDL needs to fall, your cardiovascular risk, whether you can take any statin at all, cost and insurance coverage, and how you feel about pills versus injections. These medicines are not interchangeable: they work differently, lower LDL by different amounts, and have different outcome evidence and side-effect profiles. A practical plan starts with a clear LDL goal and a careful review of why your current treatment is not enough.

When to Consider a Statin Alternative
Ezetimibe: The Simple Oral Add-On
PCSK9 Therapies: The Largest LDL Reductions
Bempedoic Acid: An Oral Option for Statin Intolerance
How the Main Options Compare
How Doctors Build a Treatment Plan
What to Ask Your Doctor

When to Consider a Statin Alternative

A nonstatin medicine is most useful when there is a specific reason for it: your LDL is still too high, your cardiovascular risk calls for more aggressive lowering, or you cannot tolerate the statin dose needed to reach your treatment goal. In many cases, a nonstatin is added to a tolerated statin rather than replacing it.

Current U.S. guidance emphasizes matching treatment intensity to a person’s overall risk and LDL goal. People who already have atherosclerotic cardiovascular disease, such as a previous heart attack, ischemic stroke, or symptomatic peripheral artery disease, generally need more aggressive LDL lowering than people at lower short-term risk. Very high-risk patients may have an LDL goal below 55 mg/dL, while other patients with established disease often have a goal below 70 mg/dL. Primary-prevention goals depend on risk, age, diabetes, chronic kidney disease, severe hypercholesterolemia, and other factors.

If your LDL is high but you are unsure how much treatment you need, it helps to understand your full risk rather than focusing on one number. Tests such as ApoB or a coronary artery calcium score may sometimes refine decisions when the answer is uncertain.

A true need for an alternative can arise in several common situations:

Partial statin intolerance: You can take a low dose or certain statins, but not enough to reach your LDL goal.
Complete statin intolerance: Repeated attempts with appropriate statin regimens cause unacceptable adverse effects, and no useful dose is tolerated.
Insufficient LDL response: You tolerate a statin but need an additional 15%, 25%, 50%, or more reduction.
Very high baseline LDL: People with familial hypercholesterolemia or LDL levels around 190 mg/dL or higher may need several therapies.
Established cardiovascular disease: Lower LDL targets often make combination therapy necessary.

The National Lipid Association recommends trying at least two statins, including one at the lowest approved daily dose, before classifying someone as statin intolerant. That matters because many people who develop symptoms on one statin can tolerate another statin, a lower dose, or a different dosing schedule. If muscle symptoms are the issue, a structured approach to statin-associated muscle pain can often preserve some statin benefit while another drug supplies the remaining LDL reduction.

Ezetimibe: The Simple Oral Add-On

Ezetimibe is often the first nonstatin medicine considered because it is a once-daily pill, is available generically, has few drug interactions, and usually lowers LDL by roughly 15% to 25%. It works mainly in the small intestine by blocking absorption of cholesterol through a transport protein called NPC1L1. The liver then pulls more LDL particles out of the bloodstream.

That mechanism is different from a statin, which reduces cholesterol production in the liver. Because the two drugs work at different steps, their effects complement each other. Someone who cannot tolerate a high-intensity statin may get a useful result from a lower statin dose plus ezetimibe. Someone who cannot take a statin at all can also use ezetimibe by itself, although the LDL reduction is usually more modest.

The major cardiovascular outcomes evidence for ezetimibe came from the IMPROVE-IT trial. More than 18,000 people who had recently experienced an acute coronary syndrome were assigned to simvastatin plus ezetimibe or simvastatin alone. Adding ezetimibe lowered LDL further and produced a modest but statistically significant reduction in major cardiovascular events over long-term follow-up. This was important because it showed that lowering LDL with a nonstatin mechanism could improve outcomes, not merely change a laboratory number.

Ezetimibe is generally well tolerated. Possible adverse effects include diarrhea, abdominal symptoms, fatigue, or muscle complaints, but serious problems are uncommon. Liver enzyme elevations can occur, particularly when ezetimibe is combined with a statin, so clinicians may check liver tests when clinically appropriate. People with significant active liver disease need individualized advice.

Ezetimibe makes particular sense when:

you need a moderate additional LDL reduction;
you prefer a pill rather than an injection;
cost or insurance access is important;
you tolerate some statin but not a high enough dose; or
your clinician wants to try the simplest add-on before moving to a stronger injectable therapy.

For a direct comparison of these two common approaches, see ezetimibe versus statins.

PCSK9 Therapies: The Largest LDL Reductions

PCSK9-targeting medicines can produce some of the largest LDL reductions available outside of specialized treatments for rare lipid disorders. The best-established options are the monoclonal antibodies evolocumab and alirocumab. They are injected under the skin, typically every two weeks or monthly depending on the drug and regimen, and can lower LDL by about 50% to 60% when added to background therapy.

PCSK9 is a protein that promotes destruction of LDL receptors on liver cells. Those receptors normally remove LDL particles from the blood. Blocking PCSK9 allows more LDL receptors to survive and recycle, so the liver clears LDL much more efficiently.

Large cardiovascular outcome trials have shown that evolocumab and alirocumab reduce events such as myocardial infarction, ischemic stroke, and coronary revascularization in high-risk patients. That combination of potent LDL lowering and outcomes evidence makes PCSK9 monoclonal antibodies especially valuable for people with established cardiovascular disease, familial hypercholesterolemia, or LDL that remains well above goal despite maximally tolerated oral treatment.

A newer PCSK9-directed medicine, inclisiran, uses small interfering RNA to reduce the liver’s production of PCSK9. After the initial and three-month doses, it is typically given every six months by a health professional. It can lower LDL by about 50%. Its infrequent dosing can be attractive for people who have trouble taking a medicine regularly. However, drug selection should reflect the most current cardiovascular outcomes evidence and guideline recommendations, because the evidence base for individual PCSK9-targeting products is not identical.

Injection-site reactions are among the more common adverse effects of PCSK9 therapies. Serious adverse effects are uncommon in trials, and monoclonal antibodies have generally shown favorable safety profiles. The larger obstacle is often practical: prior authorization, insurance rules, copays, and the need for injections.

These therapies are worth discussing when you need a very large LDL reduction or remain above goal despite statin and ezetimibe therapy. A clinician may also consider them earlier when risk is especially high. For more detail on dosing and expectations, see PCSK9 inhibitors for LDL cholesterol.

Bempedoic Acid: An Oral Option for Statin Intolerance

Bempedoic acid is a once-daily oral medicine that lowers LDL by inhibiting ATP citrate lyase, an enzyme in the cholesterol-production pathway upstream from the enzyme targeted by statins. A key practical difference is that bempedoic acid is activated mainly in the liver rather than skeletal muscle. That feature made it particularly interesting for people who report muscle symptoms with statins.

Used alone, bempedoic acid commonly lowers LDL by roughly 15% to 25%, depending on background treatment and the population studied. It can also be combined with ezetimibe in a fixed-dose pill, and the two mechanisms together can produce a substantially larger reduction than either medicine alone.

The CLEAR Outcomes trial provided the most important outcome evidence. It enrolled 13,970 patients who were unable or unwilling to take guideline-recommended statin doses because of adverse effects and who either had cardiovascular disease or were at high risk. Bempedoic acid lowered LDL by about 21% relative to placebo at six months. Over a median follow-up of about 40.6 months, the primary major cardiovascular event outcome occurred in 11.7% of the bempedoic-acid group and 13.3% of the placebo group. That corresponds to a hazard ratio of 0.87, showing a meaningful reduction in cardiovascular risk in this statin-intolerant population.

Bempedoic acid has tradeoffs. In CLEAR Outcomes, gout occurred more often with bempedoic acid than placebo, as did gallstones. Small increases in uric acid, creatinine, and liver enzymes were also seen. A person with gout, marked hyperuricemia, significant liver problems, or certain tendon issues should discuss those factors before starting it. Clinicians may check uric acid or other laboratory tests depending on medical history and symptoms.

This medicine can be a strong fit when someone wants an oral option, cannot tolerate adequate statin therapy, and needs more LDL lowering than lifestyle changes or ezetimibe alone provide. More detail is available in bempedoic acid benefits and side effects.

How the Main Options Compare

The most useful comparison is not simply “which drug is strongest?” The right question is “which option gets me from my current LDL to my goal with an acceptable burden, cost, and side-effect profile?”

Option	Typical LDL reduction	How it is taken	Cardiovascular outcomes evidence	Common practical issue
Ezetimibe	About 15%–25%	Daily pill	Yes, especially as add-on to statin	Smaller LDL reduction
PCSK9 monoclonal antibodies	About 50%–60%	Injection every 2 weeks or monthly	Strong evidence in high-risk patients	Cost, authorization, injections
Inclisiran	About 50%	Injection initially, at 3 months, then every 6 months	LDL-lowering evidence is strong; outcome evidence should be reviewed as it matures	Clinic administration and coverage
Bempedoic acid	About 15%–25%	Daily pill	Yes, including statin-intolerant patients	Gout, uric acid, gallstones
Ezetimibe + bempedoic acid	Often around 35%–40%	Daily pill or separate tablets	Each component has supportive evidence; combination lowers LDL substantially	Cost and combined tolerability

These are approximate averages, not guarantees. Your actual response can be larger or smaller. Baseline LDL, adherence, genetics, other medicines, and whether a statin is being used at the same time all matter.

It is also important not to treat these medicines as substitutes for lifestyle. Food choices, activity, body weight, smoking cessation, and control of blood pressure and diabetes reduce cardiovascular risk through pathways that medication cannot fully replace. Dietary strategies such as increasing soluble fiber and reducing excess saturated fat can add useful LDL lowering, although people at high risk should not delay indicated medication while trying lifestyle changes alone.

If the reason for treatment is a persistently high LDL number, make sure the cause has been assessed. Untreated hypothyroidism, kidney disease, certain medications, major dietary changes, and inherited conditions can all contribute. A broader review of high LDL causes and treatment can help put the medication choice in context.

How Doctors Build a Treatment Plan

A good lipid-lowering plan is usually built backward from the treatment goal. First determine how high the risk is and what LDL level or percentage reduction is appropriate. Then estimate how much each available therapy is likely to contribute.

For example, suppose your LDL is 140 mg/dL and your treatment goal is below 70 mg/dL. You need a reduction of at least 50%. Ezetimibe alone is unlikely to be enough. A tolerated statin plus ezetimibe may reach the goal for some people, while others may need a PCSK9 inhibitor. If you are truly statin intolerant, an oral combination such as bempedoic acid plus ezetimibe may produce a meaningful drop, but an injectable therapy may still be necessary if the gap is large.

After a medication change, lipid levels are generally rechecked after enough time has passed to see the treatment effect and assess adherence. Clinicians commonly repeat a lipid panel within several weeks to a few months, then monitor at longer intervals once treatment is stable. The exact timing depends on the drug, clinical urgency, and guideline being followed.

A useful decision process includes these steps:

Confirm the treatment target. Ask what LDL level or percentage reduction your clinician is aiming for and why.
Clarify statin tolerance. If you stopped a statin because of symptoms, review the dose, timing, other possible causes, and whether a lower dose or another statin is reasonable.
Calculate the treatment gap. Compare your current LDL with your goal so you know whether you need a 15% reduction or a 60% reduction.
Choose the simplest option likely to work. A low-cost pill may be enough for a modest gap; a potent injectable may be more efficient for a large gap.
Plan monitoring and follow-up. Know when to repeat lipids and which side effects should trigger a call.
Address access before abandoning a good option. If cost is the main barrier, ask about formulary alternatives, prior authorization, assistance programs, or another medicine in the same treatment pathway.

Do not stop lipid-lowering treatment for months while testing one strategy after another if you have very high cardiovascular risk. Prolonged exposure to high LDL matters. In high-risk patients with statin intolerance, current expert guidance supports using effective nonstatin treatment while continuing efforts to find any tolerable statin regimen when appropriate.

What to Ask Your Doctor

The most productive appointment is one that turns a general concern—“I cannot take statins” or “my cholesterol is still high”—into specific decisions. Bring your recent lipid results, a list of medicines and supplements, details of previous statin trials, and your insurance formulary if it is easy to access.

Consider asking:

What is my LDL goal, and what is my current percentage gap? This immediately clarifies how potent the next treatment needs to be.
Am I completely statin intolerant or only unable to tolerate a particular statin or dose? Partial tolerance can change the entire plan.
Would a low-dose statin plus ezetimibe give me enough LDL lowering? This combination is often inexpensive and effective.
If I need a 50% or greater additional reduction, should we discuss a PCSK9 therapy? Ask which product has the strongest fit for your risk, evidence, dosing preference, and insurance coverage.
Would bempedoic acid be appropriate given my history of gout or high uric acid? Personal risk factors matter more than a generic side-effect list.
Which option has evidence for preventing heart attacks or strokes in someone like me? LDL lowering is important, but outcome evidence helps distinguish among choices.
What laboratory monitoring do I need, and when should I repeat my lipid panel? Leave with a date or time window rather than an open-ended plan.
What should I do if the medicine is unaffordable? Ask before simply not filling it.

Also ask whether other risk markers should influence the decision. In selected people, an ApoB target can help assess the number of atherogenic particles, especially when triglycerides, diabetes, or metabolic disease make LDL cholesterol less informative by itself.

The central point is that “statin alternative” does not mean settling for weaker prevention. Modern treatment can combine lower statin doses with nonstatins or, when necessary, use nonstatin regimens capable of substantial LDL reduction. The best plan is the one that reaches an evidence-based target and is realistic enough for you to continue long term.

References

Disclaimer

This article is for general education and does not replace medical care. Cholesterol treatment should be individualized according to your cardiovascular risk, LDL level, other conditions, medication history, and treatment goals. Do not stop a prescribed statin or start a nonstatin cholesterol medicine without discussing the change with your clinician.